Top Authors for All Days ending 2016-12-01: GROWTH Trends @Leaders in Pharmaceutical Business Intelligence (LPBI) Group
December 1, 2016 by 2012pharmaceutical
Top Authors for All Days ending 2016-12-01: GROWTH Trends @Leaders in Pharmaceutical Business Intelligence (LPBI) Group
Curator: Aviva Lev-Ari, PhD, RN
Date |Views to Date |# of articles |NIH Clicks |Nature Clicks
12/1/2016 |
1,107,643 |
4,972 |
3,398 |
2,279 |
Be proud to be part of this team !!!
Forthcoming SEVEN e-Books in 2016 AND Eight e-Books on Amazon.com
https://pharmaceuticalintelligence.com/2016/04/24/new-e-book-titles-forthcoming-on-amazon-com-in-2016-from-lpbi-groups-biomed-e-series-forthcoming-cover-pages/
WE ARE ON AMAZON.COM
http://www.amazon.com/dp/B00DINFFYC
http://www.amazon.com/dp/B018Q5MCN8
http://www.amazon.com/dp/B018PNHJ84
http://www.amazon.com/dp/B018DHBUO6
http://www.amazon.com/dp/B013RVYR2K
http://www.amazon.com/dp/B012BB0ZF0
http://www.amazon.com/dp/B019UM909A
http://www.amazon.com/dp/B019VH97LU
GROWTH TRENDS: e-Readers, # of articles, NIH Clicks, Nature Clicks
2013, 2014, 2015, 2016
Scientific Journal Site Statistics
Date |Views to Date |# of articles |NIH Clicks |Nature Clicks
07/29/2013 217,356 1,138 1,389 705
12/01/2013 287,645 1,428 1,676 828
02/09/2014 325,039 1,665 1,793 892
03/05/2014 338,958 1,717 1,830 965
03/21/2014 347,667 1,750 1,838 974
03/31/2014 352,683 1,768 1,869 991
05/12/2014 373.696 1,878 1,944 1,035
06/18/2014 393,111 1,992 1,982 1,087
7/27/2014 418,570 2,098 2.050 1,124
9/2/2014 444,222 2,226 2,104 1,170
10/9/2014 471,117 2,337 2,147 1,216
11/4/2014 492,736 2,471 2,194 1,234
2/15/2015 572,027 2,727 2,358 1,345
3/10/2015 591,520 2,808 2,373 1,369
6/7/2015 661,215 3,007 2,562 1,535
7/27/2015 694,298 3,085 2,583 1,572
8/18/2015 709,609 3,173 2,613 1,573
02/18/2016 886,454 4,162 2,911 1,813
Date |Views to Date |# of articles |NIH Clicks |Nature Clicks
12/1/2016 |
1,107,643 |
4,972 |
3,398 |
2,279 |
Be proud to be part of this team !!!
Top Authors for all days ending 2016-12-01 (Summarized)
Author |
Views |
Aviva Lev-Ari, PhD, RN |
295,929 |
larryhbern |
|
203,736 |
tildabarliya |
43,869 |
sjwilliamspa |
|
35,934 |
Dror Nir |
|
23,073 |
Dr. Sudipta Saha |
|
19,509 |
ritusaxena |
|
14,934 |
|
Demet Sag, Ph.D., CRA, GCP |
|
12,025 |
aviralvatsa |
|
7,942 |
zraviv06 |
|
7,176 |
zs22 |
|
3,738 |
anamikasarkar |
|
3,182 |
danutdaagmailcom |
|
2,283 |
pkandala |
|
2,097 |
Gail S Thornton |
|
2,035 |
Alan F. Kaul, PharmD., MS, MBA, FCCP |
|
1,975 |
Aashir Awan, Phd |
|
1,775 |
megbaker58 |
|
1,408 |
jdpmd |
|
1,345 |
Irina Robu |
|
879 |
Ed Kislauskis |
|
546 |
howarddonohue |
|
521 |
evelinacohn |
|
344 |
David Orchard-Webb, PhD |
|
341 |
apreconasia |
|
332 |
stuartlpbi |
|
252 |
jukkakarjalainen |
|
226 |
gerag2015 |
90 |
kellyperlman |
|
59 |
Rosalind Codrington, PhD |
29 |
Debashree |
|
22 |
|
Top Posts for all days ending 2016-12-03 (Summarized)
|
|
|
|
|
|
All Time |
|
|
|
Views |
Home page / Archives |
402,487 |
Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View? – Dr. Larry Bernstein |
14,861 |
Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) Aviva Lev-Ari, et al |
9,080 |
Recent comprehensive review on the role of ultrasound in breast cancer management Dr. Dror Nir |
6,720 |
Paclitaxel vs Abraxane (albumin-bound paclitaxel) Tilda Barliya, PhD |
5,695 |
Our TEAM |
Aviva Lev-Ari, PhD, RN |
5,539 |
Mesothelin: An early detection biomarker for cancer (By Jack Andraka)
Tilda Barliya, PhD |
5,051 |
Akt inhibition for cancer treatment, where do we stand today?
Ziv Raviv, PhD |
3,843 |
Newer Treatments for Depression: Monoamine, Neurotrophic Factor & Pharmacokinetic Hypotheses – Zohi Sternberg, PhD |
3,740 |
Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care – Dr. Justin Pearlman and Aviva Lev-Ari, PhD, RN |
3,418 |
Volume One: Perspectives on Nitric Oxide in Disease Mechanisms
Editors: Dr. Larry Bernstein, Aviral Vatsa, PhD and Stephen J Williams, PhD |
3,389 |
Confined Indolamine 2, 3 dioxygenase (IDO) Controls the Hemeostasis of Immune Responses for Good and Bad – Demet Sag, PhD |
3,181 |
AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo – Stephen J Williams, PhD |
3,149 |
Apixaban (Eliquis): Mechanism of Action, Drug Comparison and Additional Indications – Aviva Lev-Ari, PhD, RN |
3,082 |
Founder |
Aviva Lev-Ari, PhD, RN |
3,075 |
BioMed e-Series – Aviva Lev-Ari, PhD, RN |
2,944 |
The mechanism of action of the drug ‘Acthar’ for Systemic Lupus Erythematosus (SLE) Aviva Lev-Ari, PhD, RN et al |
2,728 |
Introduction to Transdermal Drug Delivery (TDD) system and nanotechnology – Tilda Barliya, PhD |
2,728 |
The Centrality of Ca(2+) Signaling and Cytoskeleton Involving Calmodulin Kinases and Ryanodine Receptors in Cardiac Failure, Arterial Smooth Muscle, Post-ischemic Arrhythmia, Similarities and Differences, and Pharmaceutical Targets – Dr. Larry Bernstein, Dr. Justin Pearlman and Aviva Lev-Ari, PhD, RN |
2,715 |
VISION |
Aviva Lev-Ari, PhD, RN |
2,527 |
Alternative Designs for the Human Artificial Heart: Patients in Heart Failure – Outcomes of Transplant (donor)/Implantation (artificial) and Monitoring Technologies for the Transplant/Implant Patient in the Community – Dr. Larry Bernstein, Dr. Justin Pearlman and Aviva Lev-Ari, PhD, RN |
2,487 |
Funding, Deals & Partnerships – Aviva Lev-Ari, PhD, RN |
2,436 |
Biochemistry of the Coagulation Cascade and Platelet Aggregation – Part I
Dr. Larry Bernstein |
2,318 |
FDA Guidelines For Developmental and Reproductive Toxicology (DART) Studies for Small Molecules – Stephen J Williams, PhD |
2,260 |
Bone regeneration and nanotechnology – – Tilda Barliya, PhD |
2,252 |
“The Molecular pathology of Breast Cancer Progression” – – Tilda Barliya, PhD |
2,233 |
Causes and imaging features of false positives and false negatives on 18F-PET/CT in oncologic imaging – Dror Nir, PhD |
2,150 |
About |
Aviva Lev-Ari, PhD, RN |
2,036 |
In focus: Circulating Tumor Cells – Ritu Saxena, PhD |
2,034 |
Mitochondria: Origin from oxygen free environment, role in aerobic glycolysis, metabolic adaptation – Dr. Larry Bernstein |
2,016 |
Treatment Options for Left Ventricular Failure – Temporary Circulatory Support: Intra-aortic balloon pump (IABP) – Impella Recover LD/LP 5.0 and 2.5, Pump Catheters (Non-surgical) vs Bridge Therapy: Percutaneous Left Ventricular Assist Devices (pLVADs) and LVADs (Surgical)
Larry H Bernstein, MD, FCAP and Justin D Pearlman, MD, PhD, FACC |
1,983 |
Journal PharmaceuticalIntelligence.com – Aviva Lev-Ari, PhD, RN |
1,977 |
Pacemakers, Implantable Cardioverter Defibrillators (ICD) and Cardiac Resynchronization Therapy (CRT) – Justin D Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN |
1,967 |
Problems of vegetarianism – Sudipta Saha, PhD |
1,903 |
Sexed Semen and Embryo Selection in Human Reproduction and Fertility Treatment – Sudipta Saha, PhD |
1,844 |
DNA Structure and Oligonucleotides – Larry H Bernstein, MD, FCAP |
1,796 |
Targeting the Wnt Pathway [7.11] – Larry H Bernstein, MD, FCAP |
1,759 |
Biosimilars: CMC Issues and Regulatory Requirements – Aviva Lev-Ari, PhD, RN |
1,726 |
Interaction of enzymes and hormones – Sudipta Saha, PhD |
1,716 |
Nitric Oxide and Platelet Aggregation – Dr. Venkat S. Karra, Ph.D. |
1,713 |
CD47: Target Therapy for Cancer – Tilda Barliya, PhD |
1,712 |
Peroxisome proliferator-activated receptor (PPAR-gamma) Receptors Activation: PPARγ transrepression for Angiogenesis in Cardiovascular Disease and PPARγ transactivation for Treatment of Diabetes –
Aviva Lev-Ari, PhD, RN |
1,711 |
Introduction to Tissue Engineering; Nanotechnology applications
Tilda Barliya, PhD |
1,666 |
Non-small Cell Lung Cancer drugs – where does the Future lie? –
Ritu Saxena, PhD |
1,658 |
Nanotechnology: Detecting and Treating metastatic cancer in the lymph node – Tilda Barliya, PhD |
1,583 |
A Primer on DNA and DNA Replication – Larry H. Bernstein, MD, FCAP |
1,572 |
Lipid Metabolism – Larry H. Bernstein, MD, FCAP |
1,568 |
Outcomes in High Cardiovascular Risk Patients: Prasugrel (Effient) vs. Clopidogrel (Plavix); Aliskiren (Tekturna) added to ACE or added to ARB
Aviva Lev-Ari, PhD, RN |
1,532 |
The SCID Pig: How Pigs are becoming a Great Alternate Model for Cancer Research – Stephen J Williams, PhD |
1,489 |
Biosimilars: Intellectual Property Creation and Protection by Pioneer and by Biosimilar Manufacturers – Aviva Lev-Ari, PhD, RN |
1,459 |
|
|
|
Like this:
Like Loading...
Leave a Reply